GeneReach Biotechnology Profit Margin

The latest profit margin for 4171.TWO is -18.31% as of June 2026. That compares with -61.83% in the prior-year period — up 70.4% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside GeneReach Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4171.TWO's profit margin moved from -61.83% to -18.31% — a 70.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneReach Biotechnology's valuation or profitability profile.

Against Healthcare companies, 4171.TWO currently prints -18.31% for profit margin, while the sector average sits near 21.34%. That is roughly 185.8% below the sector mean. Large gaps often invite a closer look at GeneReach Biotechnology's growth, margins, and balance sheet.

Profit Margin shows how effectively GeneReach Biotechnology converts resources into returns. At -18.31%, 4171.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -61.83% in the prior-year period — up 70.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4171.TWO's profit margin (-18.31%), review year-over-year change from -61.83%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.